We met some suppliers and potential distributors for eight markets during Medica in Düsseldorf. We have met three of them before. The others we met for the first time as they are related to new markets.
It saves both time and money to meet everyone at a trade fair like Medica, which is the world"s largest MedTech fair. Read more by clicking on the following link: https://www.medica-tradefair.com/

We participated in the “Research Day” in Malmö with seminars and presentations under the theme "Sepsis". Very interesting and rewarding. Please read more at: http://www.vetenskaphalsa.se/forskningens-dag-2018/

An Extraordinary General Meeting was held on Monday, 19 November at QuickCool’s premises in Lund. Complementing the financing agreement that we have with the European High Growth opportunities Securitization Fund, it was decided to proceed with a rights issue for shareholders totaling SEK 6.2 million. This will enable us to handle the peaks that arise when the costs for the third party testing and procurement of components for the 0-series occur. The rights issue is already guaranteed to SEK 3 million.

The Memorandum shows that our Chairman Göran Brorsson, Lennart Sjölund, (largest shareholder, member of the board and founder), Mats Danielsson (second largest shareholder and Professor in Medical Imaging Physics at KTH, the Royal Institute of Technology, in Stockholm), Kenneth Radencrantz, and I, the undersigned and CEO, have subscription commitments equal to SEK 3 million. More information about the extraordinary general meeting may be found on: www.quickcool.se

We signed a distribution agreement for Estonia, Latvia and Lithuania with UAB Labostera. Labostera has distribution rights to other medical devices such as spectrometers, ENT-products, analytical equipment and equipment for organ transplants, to name just a few. Labostera is well established in Lithuania, but is growing rapidly in both Estonia and Latvia.

We are working intensively on adapting the components that we were forced to change in the final stages of the development of our cooling device. It is encouraging to see the great interest in our unique cooling solution when we meet potential distributors. We continue to prepare our launch by signing agreements with carefully selected partners and distributors in each individual market.

Please follow us on LinkedIn. And take advantage of additional information that is available on our website: http://www.quickcool.se/

Kind regards,
Fredrik

Fredrik Radencrantz
CEO

QuickCool AB 
Ideon Science Park
Beta 6, Scheelevägen 17 - SE-223 70 Lund - Sweden
E-mail: fredrik.radencrantz@quickcool.se Web: www.quickcool.se  
Mobile +46 (0)73 834 1188

QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to: www.quickcool.se